SG10201704908SA - Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection - Google Patents

Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection

Info

Publication number
SG10201704908SA
SG10201704908SA SG10201704908SA SG10201704908SA SG10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA SG 10201704908S A SG10201704908S A SG 10201704908SA
Authority
SG
Singapore
Prior art keywords
lymphocyte
cytotoxic
diagnosis
prevention
treatment
Prior art date
Application number
SG10201704908SA
Other languages
English (en)
Inventor
Ramila Philip
Original Assignee
Emergex Vaccines Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holdings Ltd filed Critical Emergex Vaccines Holdings Ltd
Publication of SG10201704908SA publication Critical patent/SG10201704908SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG10201704908SA 2011-06-29 2012-06-28 Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection SG10201704908SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161502365P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
SG10201704908SA true SG10201704908SA (en) 2017-07-28

Family

ID=47424544

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201704908SA SG10201704908SA (en) 2011-06-29 2012-06-28 Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
SG2013086608A SG195115A1 (en) 2011-06-29 2012-06-28 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013086608A SG195115A1 (en) 2011-06-29 2012-06-28 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection

Country Status (5)

Country Link
US (3) US9637521B2 (fr)
AU (1) AU2012275319A1 (fr)
BR (1) BR112013032421A2 (fr)
SG (2) SG10201704908SA (fr)
WO (1) WO2013003579A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637521B2 (en) 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
EP2755679B1 (fr) 2011-09-13 2017-08-02 Immunotope, Inc. Immunogènes induisant des lymphocytes t cytotoxiques utilisés pour la prévention, le traitement et le diagnostic du cancer
US10117922B2 (en) * 2014-05-13 2018-11-06 Emergex Vaccines Holding Ltd. Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development
WO2018076001A1 (fr) * 2016-10-21 2018-04-26 National Cheng Kung University Polypeptide synthétique, composition vaccinale le comprenant, et leurs utilisations
WO2019058133A2 (fr) * 2017-09-21 2019-03-28 Emergex Vaccines Holding Limited Peptides associés à la classe i de cmh pour la prévention et le traitement du virus zika
US11690904B2 (en) * 2018-01-06 2023-07-04 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of multiple flavi virus
US20220001001A1 (en) * 2018-07-13 2022-01-06 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
US11344614B2 (en) 2018-09-29 2022-05-31 Emergex Vaccines Holding Ltd. Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
EP4168028A4 (fr) * 2020-06-17 2024-10-23 Tscan Therapeutics Inc Peptides immunodominants de sars-cov-2 et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
WO2004040263A2 (fr) * 2002-10-31 2004-05-13 Health Research, Inc. Essai diagnostique pour virus du nil occidental
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
CA2772551A1 (fr) 2009-08-26 2011-03-03 Immunotope, Inc. Immunogenes cytotoxiques induisant des lymphocytes t pour prevenir, traiter et diagnostiquer un cancer
GB201106069D0 (en) * 2011-04-11 2011-05-25 Isis Innovation Peptide markers and uses thereof
US9637521B2 (en) 2011-06-29 2017-05-02 Emergex Vaccines Holdings Limited Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
EP2755679B1 (fr) 2011-09-13 2017-08-02 Immunotope, Inc. Immunogènes induisant des lymphocytes t cytotoxiques utilisés pour la prévention, le traitement et le diagnostic du cancer

Also Published As

Publication number Publication date
US10556929B2 (en) 2020-02-11
US20190106462A1 (en) 2019-04-11
US20170275338A1 (en) 2017-09-28
BR112013032421A2 (pt) 2017-01-17
US9637521B2 (en) 2017-05-02
AU2012275319A1 (en) 2013-11-14
SG195115A1 (en) 2013-12-30
US10144766B2 (en) 2018-12-04
US20140105925A1 (en) 2014-04-17
WO2013003579A1 (fr) 2013-01-03

Similar Documents

Publication Publication Date Title
SG10201704908SA (en) Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
AP3069A (en) Thienopyridine derivatives for the treatment and prvention of dengue virus infection
ZA201308617B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
EP2596741A4 (fr) Endoscope, et instrument de traitement pour endoscope
EP2470200A4 (fr) Immunogènes cytotoxiques induisant des lymphocytes t pour prévenir, traiter et diagnostiquer un cancer
AP2012006094A0 (en) Treatment and prevention of dengue virus infections.
IL234116B (en) A preparation with sialidase activity for the treatment of parainfluenza virus in patients with a deficiency in the immune system
HK1212905A1 (zh) 用於防止登革熱病毒感染的疫苗組合物
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
EP2671586A4 (fr) Pharmacothérapie pour la prévention ou le traitement du glaucome
ZA201303610B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
IL222890A0 (en) Medicaments for the treatment of il-1beta related conditions
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
HK1248535A1 (zh) 感染的治療或預防
EP2928470A4 (fr) Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue
HK1201123A1 (en) Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2554189A4 (fr) Filtre pour le traitement du sang
EP2601967A4 (fr) Médicament destiné à la prévention et au traitement des maladies provoquées par le vih ou associées au vih, y compris du sida
GB201207543D0 (en) Treatment of transfusion blood
BR112014003556A2 (pt) método de tratamento de vírus, e, composição farmacêutica
GB201121940D0 (en) Drug treating high blood pressure
EP2522360A4 (fr) Vaccin pour le traitement de la tautopathie
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain